Development of a simple score based on HBeAg and ALT for selecting patients for HBV treatment in Africa.

[1]  C. Rogier,et al.  Prevalence of chronic hepatitis B virus infection and infrastructure for its diagnosis in Madagascar: implication for the WHO’s elimination strategy , 2017, BMC Public Health.

[2]  F. Dabis,et al.  Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[3]  N. Berhe,et al.  Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa , 2017, BMC Infectious Diseases.

[4]  T. Hallett,et al.  Requirements for global elimination of hepatitis B: a modelling study. , 2016, The Lancet. Infectious diseases.

[5]  Maimuna Mendy,et al.  Implementation of an in‐house quantitative real‐time polymerase chain reaction method for Hepatitis B virus quantification in West African countries , 2016, Journal of viral hepatitis.

[6]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[7]  H. Whittle,et al.  Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.

[8]  T. Hallett,et al.  Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis. , 2016, The Lancet. Global health.

[9]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[10]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[11]  David Moher,et al.  STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies , 2015, BMJ : British Medical Journal.

[12]  H. Whittle,et al.  Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.

[13]  G. Cooke,et al.  The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa , 2015, Gut.

[14]  Farzad Noubary,et al.  Performance of an Optimized Paper-Based Test for Rapid Visual Measurement of Alanine Aminotransferase (ALT) in Fingerstick and Venipuncture Samples , 2015, PloS one.

[15]  S. Eholie,et al.  Reducing the neglected burden of viral hepatitis in Africa: strategies for a global approach. , 2015, Journal of hepatology.

[16]  Maimuna Mendy,et al.  Validation of Rapid Point-of-Care (POC) Tests for Detection of Hepatitis B Surface Antigen in Field and Laboratory Settings in the Gambia, Western Africa , 2015, Journal of Clinical Microbiology.

[17]  V. Wong,et al.  Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. , 2014, Journal of hepatology.

[18]  U. d’Alessandro,et al.  Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls: the PROLIFICA experience in The Gambia , 2014, Alimentary pharmacology & therapeutics.

[19]  V. de Lédinghen,et al.  Determination of reliability criteria for liver stiffness evaluation by transient elastography , 2013, Hepatology.

[20]  A. Hall,et al.  Evaluation of data quality at the Gambia national cancer registry , 2013, International journal of cancer.

[21]  F. Fall,et al.  Liver Stiffness Measurement and Biochemical Markers in Senegalese Chronic Hepatitis B Patients with Normal ALT and High Viral Load , 2011, PloS one.

[22]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[23]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  V. Wong,et al.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  F. Carrat,et al.  Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. , 2010, The American journal of tropical medicine and hygiene.

[26]  J. Goedert,et al.  Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa , 2010, Journal of viral hepatitis.

[27]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: validating a prognostic model , 2009, BMJ : British Medical Journal.

[28]  M. Tong,et al.  Treatment recommendations for chronic hepatitis B: An evaluation of current guidelines based on a natural history study in the United States , 2008, Hepatology.

[29]  Mei‐Hwei Chang.  Natural history and clinical management of chronic hepatitis B virus infection in children , 2008, Hepatology international.

[30]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[31]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[32]  G. Leroux-Roels,et al.  Evaluation of a New Rapid Test for the Combined Detection of Hepatitis B Virus Surface Antigen and Hepatitis B Virus e Antigen , 2002, Journal of Clinical Microbiology.

[33]  W. Mason,et al.  Geographic variation in viral load among hepatitis B carriers with differing risks of hepatocellular carcinoma. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[34]  J. Carlin,et al.  Bias, prevalence and kappa. , 1993, Journal of clinical epidemiology.

[35]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[36]  M. Dickie,et al.  Global Health Sector Strategy on Viral Hepatitis : What does it mean for Canadians ? , 2018 .

[37]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[38]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .